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Clinical phenotypeProgranulin (GRN) mutations are associated with different clinical phenotypes, including Frontotemporal
Lobar Degeneration (FTLD), Corticobasal Degeneration and Alzheimer's disease (AD). In addition, the range
of age at onset is very wide and patients presenting initial symptoms around eighty years have been
described. Previous studies demonstrated that progranulin plasma levels determination may be a reliable
method to identify GRN deletion carriers. We thus evaluated progranulin plasma levels in all patients
followed at our Alzheimer's Centre whose plasma was available (n=176) and found four patients displaying
low values. Three of them carried the CACT deletion in exon 7 and their clinical diagnosis was behavioral
variant Frontotemporal Dementia. We also identiﬁed a patient carrying a previously reported CAGT deletion
in exon 5.
Here, we report on this case. The onset of symptoms was at 77 years and the initial diagnosis was of amnestic
Mild Cognitive Impairment (aMCI), which converted to AD six months later. In the following years, the
patient also developed behavioral disturbances, gait apraxia and parkinsonian symptoms. At present, she is
84 years old and is still followed-up periodically.
This case conﬁrms progranulin plasma levels as a reliable biomarker to identify GRN deletion carriers and
discriminate between FTLD and other dementias which may mimic it. We thus encourage the inclusion of
this non-invasive and easy test in clinical practice.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In 2006mutations in progranulin gene (GRN) were identiﬁed to be
the cause of familial Frontotemporal Lobar Degeneration with
ubiquitin-positive, TAR DNA-binding protein (TARDBP, also known
as TDP-43)-positive inclusions (FTLD-U). The ﬁrst discovered muta-
tions were shown to cause haploinsufﬁciency through nonsense-
mediated mRNA decay [1,2]. Since then, several novel mutations and
variants in this gene have been found in either familial or sporadic
cases (www.molgen.ua.ac.be). Notably, as opposed to previously
known mutations in tau gene (MAPT), GRN mutations are associatedciences, “Dino Ferrari” Centre,
rsity of Milan, Via F. Sforza 35,
0320430.
io).
ll rights reserved.with widely variable clinical phenotypes, including behavioral variant
Frontotemporal Dementia (bvFTD), Progressive Aphasia (PA), Corti-
cobasal Degeneration (CBD), Alzheimer's disease (AD), amnestic Mild
Cognitive Impairment (aMCI) and Parkinson's disease (PD) (see [3]
for review). Moreover, the age at onset is largely heterogeneous,
ranging from 35 to 89 years, with a mean age of about 60 years [3].
Recently, it has been repeatedly demonstrated that carriers of
deletions in GRN display very low plasma progranulin levels as
compared with non-carriers [4–6]. As this assessment is non-invasive
and easy to perform, it may be a reliable method to identify
progranulin deletion carriers without sequencing the whole GRN
gene, which is indeed technically more complicated and even more
expensive.
Given these premises, we determined progranulin plasma levels
using an ELISA kit (AdipoGene, Korea) in all patients followed at our
Alzheimer's Centre from 2002 to 2008 whose plasma samples were
available. Samples collected were stored at −30 °C until use.
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diagnosed with AD, 45 with bvFTD and 56 with MCI or subjective
memory complaints. Informed consent was obtained from either pa-
tients or their caregiver.
2. Results and clinical case description
Four patients showed progranulin plasma levels lower than the
normality reference valuespreviously proposed [4]with ameanvalueof
36.24±12.55 ng/ml (Fig. 1). Themean progranulin plasma levels of the
remainder screened subjects were 221.25±10.05 ng/ml in the AD
group, 216,00±12.26 ng/ml in the FTLD group and 228.51±10.63 ng/
ml in the MCI-subjective memory complaints group (Fig. 1). Thus, we
performed direct sequencing of GRN in subjects displaying low values,
which demonstrated the presence of a known 4 bp deletion in GRN
exon 7 (c.813_816delCACT) in three of them. All of them had a clinical
diagnosis of bvFTD (range: 48–56 years) and none showed a positive
family history for dementia and/or behavioral problems. Unexpectedly,
we also found a previously published [1] deletion in exon 5
(c.388_391delCAGT) in a patient clinically diagnosed with AD, whose
onset was at 77 years of age. In addition,GRN genewas sequenced in all
FTLD patients, as well as in subjects with plasma GRN values b150 ng/
ml. As expected, no mutations were found in these subjects. Therefore,
using the cut-off previously proposed byGhidoni et al. [4], in accordance
with their results, we had a sensitivity (deﬁned as: real carriers/total
carriers identiﬁed through the test) and speciﬁcity (real non-carriers/
total non-carriers identiﬁed through the test) of 100%, supporting the
usefulness of the test.
Here, we report on the case clinically diagnosed as AD. The patient
came to our attention in 2003, when she was 78. She had no signiﬁcant
family history of neurological disorders; at that time, thepatient hadone
brother and four sisters aged 79, 69, 74, 76, 80 years respectively and
noneof themhad ever complained of any cognitive, behavioral ormotor
problem. The patient's sister aged 74 suffered from depression. Despite
the apparent lack of a signiﬁcant family history, the patient's mother
(who died in her eighties) was reported to suffer from behavioral
disturbances (although not documented), cardiovascular problems and
movement difﬁculties due to overweight. All the patient's siblings are
healthy at the moment.
Patient pastmedical history only revealed blood hypertension treated
withanACE-inhibitor (Ramipril 5mg/day). Shehad12yearsof education.
Her daughter ﬁrst noticed memory deﬁcits and anxiety about one year
prior to admission to our Department; at that time, the patient denied to
have memory problems and became slightly aggressive if reminded of
them. The neurological examination did not show evident deﬁcits in
cognitive functions, and was otherwise unremarkable. The patient
underwent a full neuropsychological assessment, including evaluation
of attention, calculation, logical reasoning, language, memory, praxis and
visuospatial functions. TheMiniMental State Examination (MMSE) scoreFig. 1. Plasma progranulin levels in patients clinically diagnosed with AD (n=75) or
bvFTD (n=45) and in subjects with MCI or subjective memory complaints (n=56).
The black line represents the threshold value previously proposed [4].was 27/30, therewas a slightly pathological performance at the Blessed A
scale and borderline scores at memory tests. Blood routine analysis was
normal, as well as homocysteine, folate, thyroid function and Vitamine
B12 blood levels. A CT scan of the brain was performed, only showing a
mild periventricular hypodensity of the white matter, which was
interpreted as vascular-related in accordance with the patient's age and
blood hypertension. A diagnosis of amnestic Mild Cognitive Impairment
(aMCI)wasmade, in accordancewith the criteria proposedbyPetersen et
al. [7] At that time, patient's plasma, serum and DNA were collected and
stored at−30 °C.
She underwent a second neuropsychological assessment sixmonths
later, showing a substantialworsening inmemory taskswith aMMSE of
21/30. Thus, a diagnosis of probable ADwasmade according to NINCDS-
ADRDA criteria [8] and she was started on Rivastigmin 1.5 mg twice a
day and Citalopram 10mg a day because of the presence of anxiety. Her
memory complaints progressively worsened until September 2004,
when she also developed apathy, problems in carrying out activities of
daily living and persecutory ideations. However, MMSE was 23/30 at
that time and no objective memory worsening could be detected. She
was well oriented in space but not in time. The CT scan of the brain
showed diffuse cortical and subcortical atrophy without focal lesions.
Rivastigmin was increased up to 4.5 mg twice a day, which caused
marked daily sleepiness and was therefore suspended one month later,
as no further memory complaints had occurred. In October 2005 she
underwent a thirdneuropsychological assessment;MMSEscorewas23/
30, with the same pattern observed about one year before (slight
memory impairment and pathological score at Activities of Daily Living
items). Behavioral disturbances were still present but apparently they
were less severe; furthermore, the patient gained weight owing to
hyperphagia and could not carry out the activities of daily living by
herself, so she started being helped by a caregiver. In October 2006 her
MMSE was still 22/30; persecutory ideations improved but she was
markedly disoriented in time, anosognosic, progressively lost the insight
into her deﬁcits, and was almost totally unable to take care of herself.
She was poorly compliant during the neurological examination and
aggressive with relatives; hyperfagia was still present.
In January 2007, three years and a half after the ﬁrst neurological
assessment, she also developed gait apraxia and scored 18/30 atMMSE.
Donepezil was started at 5 mg once a day, and it was well tolerated.
Two years later, at age 83, the patient also started developing
parkinsonian features, including reduced eye blinking, camptocormia,
festinating gait, difﬁcult swallowing, diffuse bradykinesia and rigidity
in the upper limbs with cogwheel phenomenon in the left arm
without resting tremor. Parkinsonian features, in particular bradyki-
nesia and swallowing impairment, showed a signiﬁcant improvement
after she was started on Levodopa 300 mg/day. At present, the patient
is 84 and shows a severely reduced interaction with the environment,
her spontaneous speech is almost abolished and she is able to perform
only simple tasks if asked; moreover, she presents frontal release
signs (glabellar and sucking reﬂexes).
3. Discussion
Results described here further conﬁrm the usefulness of plasma
progranulin level evaluation to easily detect carriers of GRN deletions,
with a sensitivity and speciﬁcity of 100%, in accordance with previous
ﬁndings [4–6]. Moreover, we found a patient carrying a deletion in
GRN exon 5 whose clinical onset was characterized by memory
deﬁcits and was initially diagnosed with aMCI and few months later
with probable AD. Her initial symptoms developed at the age of 77
and were characterized by slight memory complaints and anxiety;
later, she also developed hyperphagia, persecutory ideations and
extrapyramidal symptoms.
Despite the apparent lack of a signiﬁcant family history in this case,
the patient's mother (who died in her eighties) was reported to have
behavioral disturbances and hyperphagia. This information, along with
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mutation identiﬁed.
These data conﬁrm the observation that progranulin plasma level
determination may be a reliable method to identify progranulin
deletion carriers and encourage the inclusion of this non-invasive and
easy test in the clinical practice. In our series, 3 out of 75 (4%) FTLD
patients screened carried the delCACT mutation in GRN exon 7, thus
conﬁrming the previous observation that this mutation is one of the
most common worldwide (along with the Arg493x) [9]. This deletion
could therefore be identiﬁed through progranulin plasma level
evaluation, before undergoing a complete sequencing of the whole
GRN gene, which implies a more complex and expensive technology.
However, it still needs to be clariﬁed whether this method may be
useful to identify carriers of single base mutations. Recently, Finch et al.
analyzed a large cohort of FTD and AD patients and unaffected relatives,
conﬁrming a reduction in plasma progranulin levels in carriers of GRN
loss-of-function mutations, whereas patients carrying single base muta-
tions had partial reduction in progranulin levels, but to a lesser extent
than carriers of loss-of-function mutations [6]. In our bvFTD series,
we sequenced all GRN exons but did not ﬁnd any carrier of single base
mutations.
The biological basis explaining so low levels of progranulin in
mutation carriers is unknown. Due to the haploinsufﬁciencymechanism,
we would expect progranulin plasma levels to be 50% reduced in
mutation carriers with respect to subjects carrying two coding genes,
rather than few ng/ml. A possible mechanism could be a disequi-
librium between progranulin and granulins occurring in patients with
haploinsufﬁciency.
With regard to the patient carrying the deletion in GRN exon 5, her
clinical presentation was quite atypical. In fact, she presented with
episodic memory disorders as the ﬁrst symptom, with very mild
behavioral changes, which worsened over time. Cognitive symptoms
and senile onset lead clinicians to make a diagnosis of aMCI and later of
AD in the pre-progranulin era. Nevertheless, the patient subsequently
developed all the most common symptoms previously observed in
carriers ofGRNmutations, including behavioral disturbances, delusions,
hyperphagia and parkinsonian features.
Interestingly, in our case the disease onset was in senile age. This
conﬁrms the previous observation that the range of age at onset is
widely variable in GRN mutation carriers, although FTD is traditionally
considered a pre-senile dementia. In a recentwork by Le Ber et al., 7 out
of 32 (22%)GRNmutation carrierswere older than 65 years at onset, and
only 3 of them were over-70 [10].
So far, a few patients clinically diagnosed with aMCI or AD and
carrying a GRN mutation have been described [6,10,11]. The patient
described here is the ﬁrst one carrying this mutation and diagnosed ﬁrst
as aMCI and thenasAD. Thus, given allﬁndings emerged in the last couple
of years and the very high sensitivity and speciﬁcity of this method,
progranulin plasma level determination followed, if needed, by GRN
mutation analysis should be carried out even in patients with memory
disturbances when the progression of symptoms is unexpectedly slow
and/or when behavioral changes and parkinsonian signs coexist during
the disease course.
Extrapyramidal features have been described in association with
FTD, and they can present both at the onset of the disease and in the late
stages, making the clinical phenotype of GRN mutation carriers even
more complex and variable, including CBD, Lewy bodydementia and PD
[10–13].
Parkinsonism seems to be more frequent in GRN mutations carriers
than in non-carriers [14,15]. This may be explained with a more
severe and widespread pattern of gray matter loss which has been
demonstrated in GRN mutation carriers, who also show a greater
degeneration of substantia nigra and basal ganglia as compared to non-
carriers [14]. Our patient also showed a signiﬁcant improvement of
extrapyramidal symptoms after Levodopa treatment (300 mg/day),which is not a common feature in FTDP-17. In fact, the majority of
patients carrying a GRN mutation usually show no or modest im-
provement with Levodopa [4,16], although few cases of responders
have been reported [17].
With regard the CT brain scan of our patient, it showed cortical and
subcortical atrophy and periventricular hypodensity which was sug-
gested to be of vascular origin, given the blood hypertension and her old
age. Nevertheless, subcortical changes involving the white matter have
been described in MRI brain imaging in association with GRNmutations
[3,17], thus the observed alterationsmayhavebeennot entirely related to
a vascular etiology.
Almost seven years after the onset of symptoms, the patient
describedhere is still alive, therefore the brain pathology is not available
yet, but this piece of information will be required to demonstrate the
presence of ubiquitin and TDP-43 protein positive inclusions in the
brain, which are considered the hallmarks of FTLDwith GRNmutations.
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